Holen Sie sich die Stockscreener-App
17.05
0.59%
-0.105
Schlusskurs vom Vortag:
$16.94
Offen:
$16.9
24-Stunden-Volumen:
47,017
Relative Volume:
0.46
Marktkapitalisierung:
$422.65M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-
EPS:
-
Netto-Cashflow:
$-51.37M
1W Leistung:
-1.06%
1M Leistung:
-25.32%
6M Leistung:
-31.54%
1J Leistung:
-51.61%
1-Tages-Spanne:
$16.60
$17.68
1-Wochen-Bereich:
$16.36
$19.85
52-Wochen-Spanne:
$11.66
$42.60
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Vergleichen Sie RNAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RNAC | 16.84 | 422.65M | 26.00M | -219.71M | -51.37M | 0.00 |
| VRTX | 449.64 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St
Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat
Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada
Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com
Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com
Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com
Cartesian Therapeutics executive sells $875,042 in stock - Investing.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance
Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN
HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat
Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan
Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - GlobeNewswire
Cartesian's Novel mRNA CAR-T Therapy Data Selected for Major ASH Conference Spotlight | RNAC Stock News - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St
Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance
Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan
Insider Buying Slows, but Not for These 7 Buyers - 24/7 Wall St.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat
30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN
Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa
Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World
Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat
Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com
Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily
Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle
Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily
Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Logos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):